ad image

Pierre Fabre

1 / 1
Pierre Fabre
Positive Opinion

Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in adult patients with advanced BRAF-mutant melanoma

Pierre Fabre

PR-M08-18-NI-008Aug 02, 2018
Pierre Fabre
Clinical Data

Pierre Fabre and Array BioPharma Announce COLUMBUS Phase 3 Study Overall Survival Results in BRAF-Mutant Melanoma Will Be Presented at 2018 ASCO Annual Meeting

Pierre Fabre

PR-M05-18-NI-076May 21, 2018
Pierre Fabre
Launch

BMG Pharma S.r.l Announces the Launch of Its AFTACURE Gel and AFTACURE Spray 

Pierre Fabre

PR-M03-18-NI-010Mar 02, 2018
Array BioPharma
Clinical Trials

Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma

Array BioPharma

PR-M02-18-NI-043Feb 13, 2018
Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival
Oncology

Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival

PR-M01-18-NI-081Jan 25, 2018
1 / 1